Identification of a novel drug-resistant community-acquired Nocardia spp. in a patient with bronchiectasis

References

• Beaman BL, Beaman L. Nocardia species: host-parasite relationships. Clin Microbiol Rev 1994;7(2):213–264.
   PubMed Web of Science ®Google Scholar
• Dennis L, Kasper ASF. Harrison's TM Infectious Diseases. McGraw-Hill Education; 2017. (Filice GA, editor. Nocardiosis).
   Google Scholar
• Mamelak AN, Obana WG, Flaherty JF, et al. Nocardial brain abscess. Neurosurgery. 1994;35(4):622–631.
   PubMed Web of Science ®Google Scholar
• Martínez Tomás R, Menéndez Villanueva R, Reyes Calzada S, et al. Pulmonary nocardiosis: risk factors and outcomes. Respirology. 2007;12(3):394–400.
   PubMed Web of Science ®Google Scholar
• Ambrosioni J, Lew D, Garbino J. Nocardiosis: updated clinical review and experience at a tertiary center. Infection. 2010;38(2):89–97.
   PubMed Web of Science ®Google Scholar
• Chaussade H, Lebeaux D, Gras G, et al. Nocardia arthritis. Medicine (Baltimore). 2015;94(42):e1671.
   PubMed Web of Science ®Google Scholar
• Kandi V. Human Nocardia infections: A review of pulmonary nocardiosis. Cureus. 2015 Aug 15;7(8):e304.
   PubMedGoogle Scholar
• Woods GL, Brown-Elliott BA, Conville PS, et al. Susceptibility Testing of Mycobacteria, nocardiae, and Other Aerobic actinomycetes. 2nd ed. Wayne (PA): Clinical and Laboratory Standards Institute; 2011.
   Google Scholar
• Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America. Am J Respir Crit Care Med 2019;200(7):e45–e67.
   PubMed Web of Science ®Google Scholar
• Wilson JW. Nocardiosis: updates and clinical overview. Mayo Clin Proc 2012;87(4):403–407.
   PubMed Web of Science ®Google Scholar
• Delcher AL, Phillippy A, Carlton J, et al. Fast algorithms for large-scale genome alignment and comparison. Nucleic Acids Res 2002;30(11):2478–2483.
   PubMed Web of Science ®Google Scholar
• Kurtz S, Phillippy A, Delcher AL, et al. Versatile and open software for comparing large genomes. Genome Biol 2004;5(2):R12.
   PubMed Web of Science ®Google Scholar
• Price MN, Dehal PS, Arkin AP. Fasttree 2 – approximately maximum-likelihood trees for large alignments. PLoS One. 2010;5(3):e9490.
   PubMed Web of Science ®Google Scholar
• Yoon SH, Ha SM, Lim J, et al. A large-scale evaluation of algorithms to calculate average nucleotide identity. Antonie Van Leeuwenhoek. 2017;110(10):1281–1286.
   PubMed Web of Science ®Google Scholar
• Gerhardt P, Murray R, Costilow RN, et al. Manual of Methods for General Bacteriology. 1981.
   Google Scholar
• Smibert R, Krieg N, Gerhardt P, et al. Methods for general and molecular bacteriology. American Society for Microbiology, Washington, DC. 1994:607-654.
   Google Scholar
• CLSI/NCCLS. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. National Committee for Clinical Laboratory Standards Wayne, PA; 2003.
   Google Scholar
• Perçin D, Sümerkan B, Inci R. [Comparative evaluation of e-test and disk diffusion methods for susceptibility testing of Nocardia species]. Mikrobiyol Bul. 2011 Apr;45(2):274–279.
   PubMed Web of Science ®Google Scholar
• Wallace RJJ, Septimus EJ, Musher DM, et al. Disk diffusion susceptibility testing of Nocardia species. J Infect Dis. 1977;135(4):568–576.
   PubMed Web of Science ®Google Scholar
• Glupczynski Y, Berhin C, Janssens M, et al. Determination of antimicrobial susceptibility patterns of Nocardia spp. from clinical specimens by etest. Clin Microbiol Infect. 2006;12(9):905–912.
   PubMed Web of Science ®Google Scholar
• Woods GL, Brown-Elliott BA, Conville PS, et al. CLSI standards: guidelines for health Care excellence. Susceptibility Testing of Mycobacteria, nocardiae, and Other Aerobic actinomycetes. Wayne (PA): Clinical and Laboratory Standards Institute; 2011.
   Google Scholar
• The Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 32 nd ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute. 2016.
   Google Scholar
• Wu W, Feng Y, Zong Z. Enterobacter sichuanensis sp. nov., recovered from human urine. Int J Syst Evol Microbiol 2018;68(12):3922–3927.
   PubMed Web of Science ®Google Scholar
• Zhuang K, Liu Y, Dai Y, et al. Nocardia huaxiensis sp. nov., an actinomycete isolated from human skin. Int J Syst Evol Microbiol 2021;71(8):004970.
   Web of Science ®Google Scholar
• Goodfellow M. The family nocardiaceae. In: A Balows, HGTM Dworkin, W Harden, KH Schleifer, editor. The prokaryotes, 2nd ed. New York, N.Y.: Springer-Verlag; 1992. p. 1188–1213.
   Google Scholar
• Berd D. Laboratory identification of clinically important aerobic actinomycetes. Appl Microbiol. 1973;25(4):665–681.
   PubMedGoogle Scholar
• Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol. 2010;8(4):260–271.
   PubMed Web of Science ®Google Scholar
• Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature. 2002;416(6882):740–743.
   PubMed Web of Science ®Google Scholar
• Cangelosi GA, Do JS, Freeman R, et al. The Two-component regulatory systemmtrABIs required for morphotypic multidrug resistance inmycobacterium avium. Antimicrob Agents Chemother 2006;50(2):461–468.
   PubMed Web of Science ®Google Scholar
• Woodworth M, Saullo J, Lantos P, et al. Increasingnocardia incidence associated with bronchiectasis at a tertiary care center. Ann Am Thorac Soc. 2017;14(3):347–354.
   PubMed Web of Science ®Google Scholar
• Collaborators AR. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. lancet (London, England). 2014;399(10325):629–655.
   Google Scholar
• On J. Review on Antimicrobial Resistance Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations 2014 [cited 2021 July 7]. Available from: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf.
   Google Scholar
• Zhang X, Falagas ME, Vardakas KZ, et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis. 2015 Apr;7(4):603–615.
   PubMed Web of Science ®Google Scholar
• Jernigan JA, Hatfield KM, Wolford H, et al. Multidrug-Resistant bacterial infections in U.S. hospitalized patients, 2012-2017. N Engl J Med. 2020 Apr 2;382(14):1309–1319.
   PubMed Web of Science ®Google Scholar
• Fang FC, Schooley RT. Antimicrobial resistance — The glass Is half full. N Engl J Med. 2020;382(14):1363–1365.
   PubMed Web of Science ®Google Scholar
• Collignon P, Beggs JJ, Walsh TR, et al. Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and multivariable analysis. The Lancet Planetary Health. 2018;2(9):e398–e405.
   PubMedGoogle Scholar
• Organization WH. Global action plan on antimicrobial resistance. 2015.
   Google Scholar
• Wilson CB, Jones PW, O'Leary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J. 1997;10(8):1754–1760.
   PubMed Web of Science ®Google Scholar
• Martínez-García M, de Gracia J, Vendrell Relat M, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J. 2014;43(5):1357–1367.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–585.
   PubMed Web of Science ®Google Scholar